Definitive Chemoradiotherapy versus Trimodality Therapy for Locally Advanced Esophageal Adenocarcinoma: A Multi-Institutional Retrospective Cohort Study
The optimal management of patients with locally advanced esophageal adenocarcinoma is unclear. Neoadjuvant chemoradiotherapy followed by esophagectomy (trimodality therapy) is supported as a standard of care, but definitive chemoradiotherapy is frequently given in practice to patients who may have b...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-08, Vol.16 (16), p.2850 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 16 |
| container_start_page | 2850 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Xu, Yang Chow, Ronald Murdy, Kyle Mahsin, Md Chandereng, Theeva Sinha, Rishi Lee-Ying, Richard Abedin, Tasnima Cheung, Winson Y Thanh, Nguyen X Lee, Sangjune Laurence |
| description | The optimal management of patients with locally advanced esophageal adenocarcinoma is unclear. Neoadjuvant chemoradiotherapy followed by esophagectomy (trimodality therapy) is supported as a standard of care, but definitive chemoradiotherapy is frequently given in practice to patients who may have been surgical candidates. This multi-institutional retrospective cohort study compared the outcomes of consecutive patients diagnosed with stage II to IVA esophageal adenocarcinoma between 2004 and 2018 who planned to undergo trimodality therapy or definitive chemoradiotherapy. A total of 493 patients were included, of whom 435 intended to undergo trimodality therapy and 56 intended to undergo definitive chemoradiotherapy. After a median follow-up of 7.3 years, trimodality therapy was associated with a lower risk of locoregional failure (5-year risk, 30.5% vs. 61.3%; HR, 0.39; 95% CI, 0.24-0.62; p |
| doi_str_mv | 10.3390/cancers16162850 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11353245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A807413807</galeid><sourcerecordid>A807413807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-34a950e005dc42c85c64d9e8e434592924ddc40886271968c2eeadf1e70e58483</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpmRuKxIVLWn8lsbmg1VJKpUVIsJwtY082rhI72M5K-0_4uXi7S2krbMm2PM-8nhlPUbzG6IJSgS61chpCxA1uCK_Rs-KUoJZUTSPY8wfnk-I8xluUB6W4bdqXxQkVWIiG4NPi90forLPJbqFc9jD6oIz1qYegpl25zfJzLNfBjt6owaZduT6aOh_KlddqGHblwmz3oZjyKvqpVxtQQ74Dl81BW-dH9b5clF_mIdnqxsVk05ysd5n6Bin4OIE-BOB7H1L5Pc1m96p40akhwvlxPyt-fLpaLz9Xq6_XN8vFqtK0pamiTIkaAUK10YxoXuuGGQEcGGW1IIIwkw2I84a0WDRcEwBlOgwtgpozTs-KDwfdaf45gtHgUlCDnHLKKuykV1Y-tjjby43fSoxpTQmrs8K7o0Lwv2aISY42ahgG5cDPUVIkBGaE4Tajb5-gt34OuRB3VMsp4pj8ozZqAGld5_PDei8qFxy1DNO8ZuriP1SeBkarvcv_mu8fOVweHHQueQzQ3SeJkdw3lHzSUNnjzcPa3PN_24f-AVRXyds</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097830812</pqid></control><display><type>article</type><title>Definitive Chemoradiotherapy versus Trimodality Therapy for Locally Advanced Esophageal Adenocarcinoma: A Multi-Institutional Retrospective Cohort Study</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Xu, Yang ; Chow, Ronald ; Murdy, Kyle ; Mahsin, Md ; Chandereng, Theeva ; Sinha, Rishi ; Lee-Ying, Richard ; Abedin, Tasnima ; Cheung, Winson Y ; Thanh, Nguyen X ; Lee, Sangjune Laurence</creator><creatorcontrib>Xu, Yang ; Chow, Ronald ; Murdy, Kyle ; Mahsin, Md ; Chandereng, Theeva ; Sinha, Rishi ; Lee-Ying, Richard ; Abedin, Tasnima ; Cheung, Winson Y ; Thanh, Nguyen X ; Lee, Sangjune Laurence</creatorcontrib><description>The optimal management of patients with locally advanced esophageal adenocarcinoma is unclear. Neoadjuvant chemoradiotherapy followed by esophagectomy (trimodality therapy) is supported as a standard of care, but definitive chemoradiotherapy is frequently given in practice to patients who may have been surgical candidates. This multi-institutional retrospective cohort study compared the outcomes of consecutive patients diagnosed with stage II to IVA esophageal adenocarcinoma between 2004 and 2018 who planned to undergo trimodality therapy or definitive chemoradiotherapy. A total of 493 patients were included, of whom 435 intended to undergo trimodality therapy and 56 intended to undergo definitive chemoradiotherapy. After a median follow-up of 7.3 years, trimodality therapy was associated with a lower risk of locoregional failure (5-year risk, 30.5% vs. 61.3%; HR, 0.39; 95% CI, 0.24-0.62; p<0.001) but not distant metastases (5-year risk, 58.2% vs. 53.9%; HR, 1.21; 95% CI, 0.77-1.91; p=0.40). There were no differences in overall survival (HR, 0.78; 95% CI, 0.56-1.09; p=0.14) or cancer-specific survival (HR, 0.83; 95% CI, 0.57-1.21; p=0.33). Findings were consistent on propensity score-matched sensitivity analyses. In conclusion, trimodality therapy was associated with a lower risk of locoregional failure, but this did not translate into a significantly lower risk of distant failure or improved survival. Further studies are required to accurately estimate the trade-offs between the two treatment strategies.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16162850</identifier><identifier>PMID: 39199621</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenocarcinoma ; Age ; Cancer ; Cancer therapies ; Care and treatment ; Chemoradiotherapy ; Chemotherapy ; Combined modality therapy ; Comparative analysis ; Drug dosages ; Electronic health records ; Endoscopy ; Esophageal cancer ; Esophagus ; Estimates ; Medical records ; Metastases ; Metastasis ; Methods ; Mortality ; Observational studies ; Patients ; Radiation therapy ; Sensitivity analysis ; Statistical analysis ; Surgery ; Survival</subject><ispartof>Cancers, 2024-08, Vol.16 (16), p.2850</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c373t-34a950e005dc42c85c64d9e8e434592924ddc40886271968c2eeadf1e70e58483</cites><orcidid>0000-0003-3984-7877 ; 0000-0002-0422-6010 ; 0000-0003-0913-6046 ; 0000-0002-1280-8109 ; 0000-0001-6195-8624</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353245/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353245/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39199621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Yang</creatorcontrib><creatorcontrib>Chow, Ronald</creatorcontrib><creatorcontrib>Murdy, Kyle</creatorcontrib><creatorcontrib>Mahsin, Md</creatorcontrib><creatorcontrib>Chandereng, Theeva</creatorcontrib><creatorcontrib>Sinha, Rishi</creatorcontrib><creatorcontrib>Lee-Ying, Richard</creatorcontrib><creatorcontrib>Abedin, Tasnima</creatorcontrib><creatorcontrib>Cheung, Winson Y</creatorcontrib><creatorcontrib>Thanh, Nguyen X</creatorcontrib><creatorcontrib>Lee, Sangjune Laurence</creatorcontrib><title>Definitive Chemoradiotherapy versus Trimodality Therapy for Locally Advanced Esophageal Adenocarcinoma: A Multi-Institutional Retrospective Cohort Study</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>The optimal management of patients with locally advanced esophageal adenocarcinoma is unclear. Neoadjuvant chemoradiotherapy followed by esophagectomy (trimodality therapy) is supported as a standard of care, but definitive chemoradiotherapy is frequently given in practice to patients who may have been surgical candidates. This multi-institutional retrospective cohort study compared the outcomes of consecutive patients diagnosed with stage II to IVA esophageal adenocarcinoma between 2004 and 2018 who planned to undergo trimodality therapy or definitive chemoradiotherapy. A total of 493 patients were included, of whom 435 intended to undergo trimodality therapy and 56 intended to undergo definitive chemoradiotherapy. After a median follow-up of 7.3 years, trimodality therapy was associated with a lower risk of locoregional failure (5-year risk, 30.5% vs. 61.3%; HR, 0.39; 95% CI, 0.24-0.62; p<0.001) but not distant metastases (5-year risk, 58.2% vs. 53.9%; HR, 1.21; 95% CI, 0.77-1.91; p=0.40). There were no differences in overall survival (HR, 0.78; 95% CI, 0.56-1.09; p=0.14) or cancer-specific survival (HR, 0.83; 95% CI, 0.57-1.21; p=0.33). Findings were consistent on propensity score-matched sensitivity analyses. In conclusion, trimodality therapy was associated with a lower risk of locoregional failure, but this did not translate into a significantly lower risk of distant failure or improved survival. Further studies are required to accurately estimate the trade-offs between the two treatment strategies.</description><subject>Adenocarcinoma</subject><subject>Age</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Combined modality therapy</subject><subject>Comparative analysis</subject><subject>Drug dosages</subject><subject>Electronic health records</subject><subject>Endoscopy</subject><subject>Esophageal cancer</subject><subject>Esophagus</subject><subject>Estimates</subject><subject>Medical records</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Sensitivity analysis</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Survival</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhiMEolXpmRuKxIVLWn8lsbmg1VJKpUVIsJwtY082rhI72M5K-0_4uXi7S2krbMm2PM-8nhlPUbzG6IJSgS61chpCxA1uCK_Rs-KUoJZUTSPY8wfnk-I8xluUB6W4bdqXxQkVWIiG4NPi90forLPJbqFc9jD6oIz1qYegpl25zfJzLNfBjt6owaZduT6aOh_KlddqGHblwmz3oZjyKvqpVxtQQ74Dl81BW-dH9b5clF_mIdnqxsVk05ysd5n6Bin4OIE-BOB7H1L5Pc1m96p40akhwvlxPyt-fLpaLz9Xq6_XN8vFqtK0pamiTIkaAUK10YxoXuuGGQEcGGW1IIIwkw2I84a0WDRcEwBlOgwtgpozTs-KDwfdaf45gtHgUlCDnHLKKuykV1Y-tjjby43fSoxpTQmrs8K7o0Lwv2aISY42ahgG5cDPUVIkBGaE4Tajb5-gt34OuRB3VMsp4pj8ozZqAGld5_PDei8qFxy1DNO8ZuriP1SeBkarvcv_mu8fOVweHHQueQzQ3SeJkdw3lHzSUNnjzcPa3PN_24f-AVRXyds</recordid><startdate>20240815</startdate><enddate>20240815</enddate><creator>Xu, Yang</creator><creator>Chow, Ronald</creator><creator>Murdy, Kyle</creator><creator>Mahsin, Md</creator><creator>Chandereng, Theeva</creator><creator>Sinha, Rishi</creator><creator>Lee-Ying, Richard</creator><creator>Abedin, Tasnima</creator><creator>Cheung, Winson Y</creator><creator>Thanh, Nguyen X</creator><creator>Lee, Sangjune Laurence</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3984-7877</orcidid><orcidid>https://orcid.org/0000-0002-0422-6010</orcidid><orcidid>https://orcid.org/0000-0003-0913-6046</orcidid><orcidid>https://orcid.org/0000-0002-1280-8109</orcidid><orcidid>https://orcid.org/0000-0001-6195-8624</orcidid></search><sort><creationdate>20240815</creationdate><title>Definitive Chemoradiotherapy versus Trimodality Therapy for Locally Advanced Esophageal Adenocarcinoma: A Multi-Institutional Retrospective Cohort Study</title><author>Xu, Yang ; Chow, Ronald ; Murdy, Kyle ; Mahsin, Md ; Chandereng, Theeva ; Sinha, Rishi ; Lee-Ying, Richard ; Abedin, Tasnima ; Cheung, Winson Y ; Thanh, Nguyen X ; Lee, Sangjune Laurence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-34a950e005dc42c85c64d9e8e434592924ddc40886271968c2eeadf1e70e58483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adenocarcinoma</topic><topic>Age</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Combined modality therapy</topic><topic>Comparative analysis</topic><topic>Drug dosages</topic><topic>Electronic health records</topic><topic>Endoscopy</topic><topic>Esophageal cancer</topic><topic>Esophagus</topic><topic>Estimates</topic><topic>Medical records</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Sensitivity analysis</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Yang</creatorcontrib><creatorcontrib>Chow, Ronald</creatorcontrib><creatorcontrib>Murdy, Kyle</creatorcontrib><creatorcontrib>Mahsin, Md</creatorcontrib><creatorcontrib>Chandereng, Theeva</creatorcontrib><creatorcontrib>Sinha, Rishi</creatorcontrib><creatorcontrib>Lee-Ying, Richard</creatorcontrib><creatorcontrib>Abedin, Tasnima</creatorcontrib><creatorcontrib>Cheung, Winson Y</creatorcontrib><creatorcontrib>Thanh, Nguyen X</creatorcontrib><creatorcontrib>Lee, Sangjune Laurence</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Yang</au><au>Chow, Ronald</au><au>Murdy, Kyle</au><au>Mahsin, Md</au><au>Chandereng, Theeva</au><au>Sinha, Rishi</au><au>Lee-Ying, Richard</au><au>Abedin, Tasnima</au><au>Cheung, Winson Y</au><au>Thanh, Nguyen X</au><au>Lee, Sangjune Laurence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Definitive Chemoradiotherapy versus Trimodality Therapy for Locally Advanced Esophageal Adenocarcinoma: A Multi-Institutional Retrospective Cohort Study</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-08-15</date><risdate>2024</risdate><volume>16</volume><issue>16</issue><spage>2850</spage><pages>2850-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The optimal management of patients with locally advanced esophageal adenocarcinoma is unclear. Neoadjuvant chemoradiotherapy followed by esophagectomy (trimodality therapy) is supported as a standard of care, but definitive chemoradiotherapy is frequently given in practice to patients who may have been surgical candidates. This multi-institutional retrospective cohort study compared the outcomes of consecutive patients diagnosed with stage II to IVA esophageal adenocarcinoma between 2004 and 2018 who planned to undergo trimodality therapy or definitive chemoradiotherapy. A total of 493 patients were included, of whom 435 intended to undergo trimodality therapy and 56 intended to undergo definitive chemoradiotherapy. After a median follow-up of 7.3 years, trimodality therapy was associated with a lower risk of locoregional failure (5-year risk, 30.5% vs. 61.3%; HR, 0.39; 95% CI, 0.24-0.62; p<0.001) but not distant metastases (5-year risk, 58.2% vs. 53.9%; HR, 1.21; 95% CI, 0.77-1.91; p=0.40). There were no differences in overall survival (HR, 0.78; 95% CI, 0.56-1.09; p=0.14) or cancer-specific survival (HR, 0.83; 95% CI, 0.57-1.21; p=0.33). Findings were consistent on propensity score-matched sensitivity analyses. In conclusion, trimodality therapy was associated with a lower risk of locoregional failure, but this did not translate into a significantly lower risk of distant failure or improved survival. Further studies are required to accurately estimate the trade-offs between the two treatment strategies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39199621</pmid><doi>10.3390/cancers16162850</doi><orcidid>https://orcid.org/0000-0003-3984-7877</orcidid><orcidid>https://orcid.org/0000-0002-0422-6010</orcidid><orcidid>https://orcid.org/0000-0003-0913-6046</orcidid><orcidid>https://orcid.org/0000-0002-1280-8109</orcidid><orcidid>https://orcid.org/0000-0001-6195-8624</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-08, Vol.16 (16), p.2850 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11353245 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Adenocarcinoma Age Cancer Cancer therapies Care and treatment Chemoradiotherapy Chemotherapy Combined modality therapy Comparative analysis Drug dosages Electronic health records Endoscopy Esophageal cancer Esophagus Estimates Medical records Metastases Metastasis Methods Mortality Observational studies Patients Radiation therapy Sensitivity analysis Statistical analysis Surgery Survival |
| title | Definitive Chemoradiotherapy versus Trimodality Therapy for Locally Advanced Esophageal Adenocarcinoma: A Multi-Institutional Retrospective Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T00%3A22%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Definitive%20Chemoradiotherapy%20versus%20Trimodality%20Therapy%20for%20Locally%20Advanced%20Esophageal%20Adenocarcinoma:%20A%20Multi-Institutional%20Retrospective%20Cohort%20Study&rft.jtitle=Cancers&rft.au=Xu,%20Yang&rft.date=2024-08-15&rft.volume=16&rft.issue=16&rft.spage=2850&rft.pages=2850-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16162850&rft_dat=%3Cgale_pubme%3EA807413807%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3097830812&rft_id=info:pmid/39199621&rft_galeid=A807413807&rfr_iscdi=true |